Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus (original) (raw)
Related papers
Serum and urinary cytokine levels of SLE patients
Die Pharmazie, 2012
Systemic lupus erythematosus (SLE) is a chronic, relapsing, polysystemic autoimmune disease with various clinical signs. The prognosis of SLE patients is influenced by neuropsychiatric and renal involvement. Lupus nephritis (LN) is present in 40-60% of patients. Classical laboratory parameters are not sensitive and specific in prediction renal flares, over the last few years there has been a growing interest in searching novel lupus biomarkers predicting future flares. Our goal was to detect serum and urinary level of cytokines in 36 patients with lupus nephritis (34 female and 2 male, mean age: 43.36 +/- 11.53 years), 23 patients with SLE without renal involvement (19 women and 4 men, mean age: 54 +/- 8.71) (both groups followed by the 3rd Department of Internal Medicine, Division of Clinical Immunology, University of Debrecen) and 30 healthy controls (23 female and 7 male, mean age: 45.5 +/- 12.4). Serum IL-1 (interleukin), IL-2 (both p < 0.05), IL-6, IL-13 and IFN-gamma (p <...
Clinical & Experimental Immunology, 2008
Interleukin-2 receptor (IL-2R) is expressed and released predominantly by activated T cells. In order to investigate whether disease exacerbations of systemic lupus erythematosus (SLE) are preceded by T cell activation, we prospectively measured levels of IL-2R once a month, from 6 months prior to exacerbations until I month afterwards. To assess the temporal relation between T cell activation and B cell activation, we measured, in addition, levels of anti-dsDNA, complement C3/C4, and total IgG. During a mean follow-up period of 23 months, 40 exacerbations occurred in 21 out of the 71 participating patients. For the present study one exacerbation per patient was evaluated. During exacerbation levels of IL-2R were increased in 18 out of the 21 cases and correlated with levels of anti-dsDNA (P <0-02), C3 (P <0-02), and C4 (P < 0-0 1), but not with the score of the disease activity index. Levels of IL-2R rose prior to the excerbation (P < 0-02) and fell afterwards following treatment (P< 0 05). Even in the absence of disease activity or during minor disease symptoms IL-2R levels were higher (P<0-01) than in healthy controls. Sixteen out of the 21 exacerbations (76%) were preceded by a significant increase in IL-2R. Changes in levels of anti-dsDNA and complement C3/C4 tended to precede changes in levels of IL-2R. We conclude that increased levels of IL-2R, compatible with T cell activation, are present in SLE already during inactive disease. These levels further increased prior to exacerbations of disease. As such, IL-2R is an indicator of disease activity in SLE. Serial measurement of IL-2R is a sensitive test for predicting disease exacerbations of SLE.
Involvement of IL-33 in the Pathophysiology of Systemic Lupus Erythematosus: Review
International Journal of Molecular Sciences, 2022
IL-33 is a newly discovered cytokine displaying pleiotropic localizations and functions. More specifically, it also functions as an alarmin, following its release from cells undergoing cell death or necrosis, to alert the innate immune system. The role of IL-33 has been underlined in several inflammatory and autoimmune diseases including systemic lupus erythematosus (SLE). The expressions of IL-33 as well as its receptor, ST2, are significantly upregulated in SLE patients and in patients with lupus nephritis. This review discusses the involvement of IL-33 in the pathology of SLE.
Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations
Arthritis research & therapy, 2018
Patients with SLE display marked clinical and immunlogical heterogeneity. The purpose of the study was to investigate patterns of serum cytokines in patients with active and stable systemic lupus erythematosus (SLE) and to determine how they relate to clinical phenotype. Serum levels of 10 cytokines were measured retrospectively in a cohort of patients with SLE and in healthy controls using a high-sensitivity multiplex bead array. Disease activity was determined using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and British Isles Lupus Assessment Group (BILAG-2004) indices. Logistic regression models were used to determine the association between cytokine levels and active SLE. Principal component analysis (PCA) and cluster analysis was then used to identify subgroups of patients on the basis of cytokine levels. Serum chemokine (C-X-C motif) ligand 10 (CXCL10) and CXCL13 were significantly higher in patients with SLE compared to healthy controls. Two cyto...
Journal of analytical research in clinical medicine, 2018
Systemic lupus erythematosus (SLE) is a relatively common disease among the patients referred to the rheumatology clinics. Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), as a cytokine, is a member of TNF family, and CD160 is an essential natural killer (NK) cell activator, both of which have been argued to be associated with SLE activity. Here, we aimed to evaluate the serum levels of sTWEAK and CD160 and their association with SLE activity. In a descriptive cross-sectional study, 48 patients with SLE, as the case group, and 40 healthy subjects, as controls, were enrolled. SLE activity was assessed using SLE Disease Activity Index (SLEDAI) in the case group. Moreover, the serum levels of sTWEAK and CD160 were determined using enzyme linked immunosorbent assays (ELISA) method in both groups. Mean serum level of sTWEAK was 19.09% lower in the control group compared to the case group (730.15 ± 170.21 pg/ml vs. 895.39 ± 451.25 pg/ml, respectively). Further, mean serum level of CD160 was 47.31% lower in the healthy subjects than that of SLE patients (206.16 ± 88.97 pg/ml vs 391.30 ± 283.46 pg/ml, respectively). The differences in both occasions were found to be significant (P = 0.013 and P =0.001, respectively). Mean SLEDAI in the patients was 8.68 ± 4.00. There was no significant correlation between serum levels of sTWEAK and CD160 with SLE activity. The serum levels of sTWEAK and CD160 markers in patients with SLE are significantly higher than those of healthy subjects. However, we found no correlation of these markers with the disease activity.
Clinical Rheumatology, 2013
We assessed the relationship between the serum levels of antibodies against double-stranded DNA (dsDNA), C1q, nucleosomes, histones, C3 and C4 complement components with one another, with organ involvement and overall disease activity in patients with systemic lupus erythematosus (SLE). One hundred seventy-five sera from 99 patients with SLE, 31 sera of patients with other connective tissue diseases, and 20 sera from healthy blood donors were tested. SLE disease activity was assessed by modified SLEDAI-2K (M-SLEDAI-2K), not including complement and anti-dsDNA descriptors. Anti-dsDNA antibodies were measured by indirect immunofluorescence on Crithidia luciliae (CLIFT), standard enzyme-linked immunosorbent assay (ELISA) and ELISA for high-avidity antibodies. The most significant risk factor for renal involvement were anti-C1q antibodies (OR=3.88, p<0.05), high-avidity anti-dsDNA antibodies for polyserositis (OR=7.99, p<0.01), anti-histone antibodies for joint involvement (OR = 2.75, p <0.05), and low C3 for cytopenia (OR=11.96, p<0.001) and mucocutaneous lesions (OR =3.32, p <0.01). Multiple linear regression analysis showed that disease activity in SLE could be predicted by the levels of antibodies against dsDNA determined by standard (p<0.05) and high-avidity (p<0.001) ELISA, and inversely associated with concentration of C3 (p<0.001). Using stepwise method, high-avidity anti-dsDNA antibodies were found to be in the closest association to M-SLEDAI-2K. Moreover, positive test for high-avidity anti-dsDNA antibodies appeared as an independent risk factor for moderately to severely active disease (M-SLEDAI-2K>5) (OR =5.5, p<0.01). The presence of high-avidity anti-dsDNA antibodies represented a risk for renal, joint, and most importantly for serosal involvement. Our results suggest that simple and reliable ELISA for high-avidity anti-dsDNA antibodies is the test of good clinical utility for the assessment of global SLE activity.
Journal of Bioscience and Applied Research
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that has a multifactorial etiology. T-Lymphocytes are essential in SLE pathogenesis. It plays a crucial role in autoantibody production and the subsequent immune complex formation, which may induce or directly damage multiple organs. This study was carried out aiming to quantify certain T lymphocyte subsets (CD3 + , CD4 + , and CD8 +) in SLE patients and to elucidate if there is a possible influence of disease activity scores and clinical manifestations. Patients and Methods: This study included 100 SLE patients with various disease activity scores (SLEDAI) and 100 healthy age and sex-matched controls. The frequency of CD3 + , CD4 + , and CD8 + was assessed by flow cytometry. Results: A significant up-regulation in CD3 + (P<0.01), CD8 + (P<0.001) coincides with a significant downregulation in CD4 + cells (P<0.001) were detected in SLE patients compared to controls. A significant up-regulation in CD4 + (P<0.05) was demonstrated in active SLE patients compared with the inactive form of the disease. On the other hand, no significant change was observed in the frequency of CD3 + and CD8 + T cell subsets between active and inactive patients. Arthritic patients have a significant reduction in CD3 + and CD4 + T cells while those with Vasculities significantly reduce in CD4+, CD8+ compared with SLE patients without these manifestations.
Biomedical and Pharmacology Journal , 2019
Systemic Lupus Erythematosus(SLE) and systemic sclerosis(SSc) are systemic inflammatory autoimmune disorders characterized by a large spectrum of clinical and laboratory features.The aim of the present study was to investigate the possible use of serum level of soluble intercellular adhesion molecule-1(sICAM-1) and soluble interleukin-2 receptor (sIL-2Ra) as biomarkers for monitoring of SLE and SSc disease activity.Moreover,it aimed to compare the specificity and sensitivity as well as cutoff value of both biomarkers in a sample of Egyptian patients.50 SLE patients, 30 SScpatients and 60 age and sex matched healthy controls were enrolled in our study. sICAM-1and sIL-2Ra were measured in serum samples obtained from all participants. In addition toErythosedimentation rate(ESR), complete blood count (CBC),Antineuclearantibodies (ANA) estimation,disease activity of both diseases were also assessed.sICAM-1and sIL-2Ra levels were higher in SLE and SSc patients versus control.Both parameters are correlated with each other as well as the activity parameters.A cutoff levels of 455.59 (ng/ml) &2525935(pg/ml) in both SLE & SSs respectively was observed with the highest specificity and sensitivity.It could be concluded that sICAM-1 and sIL-2Ra are noninvasive biomarkers for SLE and SScthat could play a pathophysiologic role in development and progression of both diseases. Moreover, sICAM-1 and sIL-2Ra are correlated with the disease activity at cutoff values of 455.59 (ng/ml) &2525935(pg/ml) respectively.
Egyptian journal of Immunology
Interleukin-33 (IL-33) is a member of the IL-1 cytokine family and is associated with the development of different autoimmune diseases as systemic lupus erythematosus (SLE). So, the purpose of this cross-sectional study was to measure the serum IL-33 in children with SLE (c-SLE) in relation to their SLE disease activity index. This study was conducted upon 50 c-SLE patients in comparison to 50 normal matched children as a control group. Disease activity was assessed according to SLE Disease Activity Index (SLEDAI-2K). Serum IL-33 was measured by an Enzyme-linked immunosorbent assay (ELISA). Serum IL-33 was significantly higher in c-SLE patients (median: 157.47, IQR:64.49-237.57ng/l) than controls (median: 10.9, IQR: 10.04-12.51ng/L) (P= 0.001) and negatively correlated with serum C3 and C4 levels. Serum IL-33 levels were significantly higher in high disease activity status (HDAS) patients (SLEDAI-2K ≥ 10) (298.47 ± 78.84ng/l) than lupus low disease activity status (LLDAS) patients (...